Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,52,11753,DB00990,Exemestane
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,35,11754,DB00990,Exemestane
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,30,11755,DB00990,Exemestane
,34041638,Ctrough,The optimal Ctrough cutoff predicting DLT development was 17.3 ng/mL.,Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,33999,DB00990,Exemestane
≥,34041638,Ctrough,"The cumulative incidence of DLTs was significantly higher in patients with Ctrough ≥17.3 ng/mL than in other patients (sub-hazard ratio 4.87, 95 % confidence interval [CI] 1.53-15.5; P = 0.007).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,34000,DB00990,Exemestane
,34041638,PFS,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,327,34001,DB00990,Exemestane
,34041638,PFS,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,194,34002,DB00990,Exemestane
,34041638,steady-state Ctrough,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,327,34003,DB00990,Exemestane
,34041638,steady-state Ctrough,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,194,34004,DB00990,Exemestane
,34041638,Ctrough,The suggested upper threshold for the therapeutic window of everolimus Ctrough was 17.3 ng/mL.,Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,34005,DB00990,Exemestane
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],20.6,51898,DB00990,Exemestane
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],54.0,51899,DB00990,Exemestane
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],38.9,51900,DB00990,Exemestane
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],198.0,51901,DB00990,Exemestane
,21641878,Extraction recoveries,"Extraction recoveries of exemestane and internal standard were 79.7-86.2% and 82.9-83.6%, respectively.",Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21641878/),%,79.7-86.2,60024,DB00990,Exemestane
,21641878,Extraction recoveries,"Extraction recoveries of exemestane and internal standard were 79.7-86.2% and 82.9-83.6%, respectively.",Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21641878/),%,82.9-83.6,60025,DB00990,Exemestane
,14671195,terminal half-life,The terminal half-life was 8.9 h.,"Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671195/),h,8.9,86655,DB00990,Exemestane
,20329658,Cmax,"The geometric mean Cmax of exemestane for the reference and test products was 21.48 and 20.14 ng/mL, respectively.",Bioequivalence of exemestane in post-menopausal females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329658/),[ng] / [ml],21.48,97982,DB00990,Exemestane
,20329658,Cmax,"The geometric mean Cmax of exemestane for the reference and test products was 21.48 and 20.14 ng/mL, respectively.",Bioequivalence of exemestane in post-menopausal females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329658/),[ng] / [ml],20.14,97983,DB00990,Exemestane
,20329658,AUC(0-infinity),The corresponding mean AUC(0-infinity) was 87.12 and 86.90 ng x h/mL.,Bioequivalence of exemestane in post-menopausal females. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329658/),[h·ng] / [ml],87.12,97984,DB00990,Exemestane
,20329658,AUC(0-infinity),The corresponding mean AUC(0-infinity) was 87.12 and 86.90 ng x h/mL.,Bioequivalence of exemestane in post-menopausal females. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329658/),[h·ng] / [ml],86.90,97985,DB00990,Exemestane
,20329658,Tmax,"The median Tmax for both products under investigation appeared at 1.70 and 1.97 h, respectively.",Bioequivalence of exemestane in post-menopausal females. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329658/),h,1.70,97986,DB00990,Exemestane
,20329658,Tmax,"The median Tmax for both products under investigation appeared at 1.70 and 1.97 h, respectively.",Bioequivalence of exemestane in post-menopausal females. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329658/),h,1.97,97987,DB00990,Exemestane
,18757262,Maximum fulvestrant concentration,Maximum fulvestrant concentration (19.7 ng/mL) was observed at an average of 12 days within the first month and maintained at 12-15 ng/mL throughout the remainder of the dosing period.,Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757262/),[ng] / [ml],19.7,107154,DB00990,Exemestane
,18757262,Maximum fulvestrant concentration,Maximum fulvestrant concentration (19.7 ng/mL) was observed at an average of 12 days within the first month and maintained at 12-15 ng/mL throughout the remainder of the dosing period.,Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757262/),[ng] / [ml],12-15,107155,DB00990,Exemestane
,18316794,TTP,"Median TTP was 3.7 months in both groups (hazard ratio = 0.963; 95% CI, 0.819 to 1.133; P = .6531).","Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316794/),month,3.7,116367,DB00990,Exemestane
,18316794,overall response rate,The overall response rate (7.4% v 6.7%; P = .736) and clinical benefit rate (32.2% v 31.5%; P = .853) were similar between fulvestrant and exemestane respectively.,"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316794/),%,7.4,116368,DB00990,Exemestane
,18316794,overall response rate,The overall response rate (7.4% v 6.7%; P = .736) and clinical benefit rate (32.2% v 31.5%; P = .853) were similar between fulvestrant and exemestane respectively.,"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316794/),%,6.7,116369,DB00990,Exemestane
,18316794,clinical benefit rate,The overall response rate (7.4% v 6.7%; P = .736) and clinical benefit rate (32.2% v 31.5%; P = .853) were similar between fulvestrant and exemestane respectively.,"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316794/),%,32.2,116370,DB00990,Exemestane
,18316794,clinical benefit rate,The overall response rate (7.4% v 6.7%; P = .736) and clinical benefit rate (32.2% v 31.5%; P = .853) were similar between fulvestrant and exemestane respectively.,"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316794/),%,31.5,116371,DB00990,Exemestane
,18316794,duration of clinical benefit,"Median duration of clinical benefit was 9.3 and 8.3 months, respectively.","Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316794/),month,9.3,116372,DB00990,Exemestane
,18316794,duration of clinical benefit,"Median duration of clinical benefit was 9.3 and 8.3 months, respectively.","Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316794/),month,8.3,116373,DB00990,Exemestane
,31201904,polydispersity index,"EXE-loaded NLCs were spherical in shape and with a hydrodynamic diameter of 131.3 ± 2.43 nm, polydispersity index 0.205 ± 0.06, and percentage entrapment efficiency 85.6 ± 1.20%.","Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31201904/),,0.205,120354,DB00990,Exemestane
,31201904,percentage entrapment efficiency,"EXE-loaded NLCs were spherical in shape and with a hydrodynamic diameter of 131.3 ± 2.43 nm, polydispersity index 0.205 ± 0.06, and percentage entrapment efficiency 85.6 ± 1.20%.","Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31201904/),%,85.6,120355,DB00990,Exemestane
,30096831,run time,The run time was 6 min.,A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096831/),min,6,142045,DB00990,Exemestane
,15014897,AUC(0- infinity ),"Thus, the geometric mean AUC(0- infinity ) values were 41.71 (90% CI 32.2 to 54.0), 99.02 (76.5 to 128.2) and 118.59 ng.h/ml (90.2 to 156.0) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively ( P<0.01).",The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014897/),[h·ng] / [ml],41.71,163144,DB00990,Exemestane
,15014897,AUC(0- infinity ),"Thus, the geometric mean AUC(0- infinity ) values were 41.71 (90% CI 32.2 to 54.0), 99.02 (76.5 to 128.2) and 118.59 ng.h/ml (90.2 to 156.0) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively ( P<0.01).",The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014897/),[h·ng] / [ml],99.02,163145,DB00990,Exemestane
,15014897,AUC(0- infinity ),"Thus, the geometric mean AUC(0- infinity ) values were 41.71 (90% CI 32.2 to 54.0), 99.02 (76.5 to 128.2) and 118.59 ng.h/ml (90.2 to 156.0) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively ( P<0.01).",The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014897/),[h·ng] / [ml],118.59,163146,DB00990,Exemestane
,15014897,AUC(0- infinity ),"Renal impairment was also associated with two- to threefold increases in AUC(0- infinity ): 34.64 (90% CI 23.9 to 50.2), 94.10 (64.9 to 136.4) and 65.52 ng.h/ml (46.5 to 92.4) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively ( P<0.05).",The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014897/),[h·ng] / [ml],34.64,163147,DB00990,Exemestane
,15014897,AUC(0- infinity ),"Renal impairment was also associated with two- to threefold increases in AUC(0- infinity ): 34.64 (90% CI 23.9 to 50.2), 94.10 (64.9 to 136.4) and 65.52 ng.h/ml (46.5 to 92.4) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively ( P<0.05).",The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014897/),[h·ng] / [ml],94.10,163148,DB00990,Exemestane
,15014897,AUC(0- infinity ),"Renal impairment was also associated with two- to threefold increases in AUC(0- infinity ): 34.64 (90% CI 23.9 to 50.2), 94.10 (64.9 to 136.4) and 65.52 ng.h/ml (46.5 to 92.4) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively ( P<0.05).",The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014897/),[h·ng] / [ml],65.52,163149,DB00990,Exemestane
,12146002,response rate (CR + PR),"The response rate (CR + PR) was 24.2% (8.33%), which exceeded the minimum number (6 cases) required to evaluate efficacy.",[Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12146002/),%,24.2,163476,DB00990,Exemestane
,12538502,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) are 41-48 h, 2-4 days, and 27 h, respectively.",Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),h,41-48,186734,DB00990,Exemestane
,12538502,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) are 41-48 h, 2-4 days, and 27 h, respectively.",Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),d,2-4,186735,DB00990,Exemestane
,12538502,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) are 41-48 h, 2-4 days, and 27 h, respectively.",Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),h,27,186736,DB00990,Exemestane
,12538502,Time to steady-state plasma levels,Time to steady-state plasma levels is 7 days for both anastrozole and exemestane and 60 days for letrozole.,Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),d,7,186737,DB00990,Exemestane
,12538502,Time to steady-state plasma levels,Time to steady-state plasma levels is 7 days for both anastrozole and exemestane and 60 days for letrozole.,Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),d,60,186738,DB00990,Exemestane
,15752382,k12,"A three-compartment model with first-order elimination rate best described exemestane disposition (k12 0.454, k21 0.158, k13 0.174, k31 0.016 and k 0.738 h(-1)).",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),,0.454,188705,DB00990,Exemestane
,15752382,k21,"A three-compartment model with first-order elimination rate best described exemestane disposition (k12 0.454, k21 0.158, k13 0.174, k31 0.016 and k 0.738 h(-1)).",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),,0.158,188706,DB00990,Exemestane
,15752382,k13,"A three-compartment model with first-order elimination rate best described exemestane disposition (k12 0.454, k21 0.158, k13 0.174, k31 0.016 and k 0.738 h(-1)).",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),,0.174,188707,DB00990,Exemestane
,15752382,k31,"A three-compartment model with first-order elimination rate best described exemestane disposition (k12 0.454, k21 0.158, k13 0.174, k31 0.016 and k 0.738 h(-1)).",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),1/[h],0.016,188708,DB00990,Exemestane
,15752382,k,"A three-compartment model with first-order elimination rate best described exemestane disposition (k12 0.454, k21 0.158, k13 0.174, k31 0.016 and k 0.738 h(-1)).",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),1/[h],0.738,188709,DB00990,Exemestane
,15752382,ka,"Absorption was described by a mono-exponential function [ka 2.3 (SCT after fasting), 1.1 (SCT after food) and 7.6 h(-1) (suspension); lag time 0.2 h].",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),1/[h],2.3,188710,DB00990,Exemestane
,15752382,ka,"Absorption was described by a mono-exponential function [ka 2.3 (SCT after fasting), 1.1 (SCT after food) and 7.6 h(-1) (suspension); lag time 0.2 h].",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),1/[h],1.1,188711,DB00990,Exemestane
,15752382,ka,"Absorption was described by a mono-exponential function [ka 2.3 (SCT after fasting), 1.1 (SCT after food) and 7.6 h(-1) (suspension); lag time 0.2 h].",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),1/[h],7.6,188712,DB00990,Exemestane
,15752382,lag time,"Absorption was described by a mono-exponential function [ka 2.3 (SCT after fasting), 1.1 (SCT after food) and 7.6 h(-1) (suspension); lag time 0.2 h].",A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),h,0.2,188713,DB00990,Exemestane
,15752382,zero-order synthesis rate,The PD model assumed that E1S plasma concentrations are determined by a zero-order synthesis rate (6.5 pg ml(-1) h(-1)) and a first-order elimination constant (0.032 h(-1)).,A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),[pg] / [h·ml],6.5,188714,DB00990,Exemestane
,15752382,first-order elimination constant,The PD model assumed that E1S plasma concentrations are determined by a zero-order synthesis rate (6.5 pg ml(-1) h(-1)) and a first-order elimination constant (0.032 h(-1)).,A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),1/[h],0.032,188715,DB00990,Exemestane
,15752382,C50,Exemestane inhibited E1S synthesis with a C50 value of 22.1 pg ml(-1).,A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752382/),[pg] / [ml],22.1,188716,DB00990,Exemestane
,20479064,MTD,The MTD of tremelimumab with exemestane was 6 mg/kg every 90 days.,Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479064/),[mg] / [kg],6,206184,DB00990,Exemestane
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],27,207812,DB00990,Exemestane
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],221,207813,DB00990,Exemestane
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],343,207814,DB00990,Exemestane
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],414,207815,DB00990,Exemestane
,12404296,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively.","An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),h,41-48,240675,DB00990,Exemestane
,12404296,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively.","An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),d,2-4,240676,DB00990,Exemestane
,12404296,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively.","An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),h,27,240677,DB00990,Exemestane
,12404296,time to steady-state plasma levels,The time to steady-state plasma levels was 7 days for both anastrozole and exemestane and 60 days for letrozole.,"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),d,7,240678,DB00990,Exemestane
,12404296,time to steady-state plasma levels,The time to steady-state plasma levels was 7 days for both anastrozole and exemestane and 60 days for letrozole.,"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),d,60,240679,DB00990,Exemestane
,30259313,Ctrough,"Among 44 evaluable patients, the geometric mean (GM) Ctrough was higher in patients with toxicity compared to patients without (17.4 versus 12.3 μg/L (p = 0.02)).",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],17.4,242948,DB00990,Exemestane
,30259313,Ctrough,"Among 44 evaluable patients, the geometric mean (GM) Ctrough was higher in patients with toxicity compared to patients without (17.4 versus 12.3 μg/L (p = 0.02)).",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],12.3,242949,DB00990,Exemestane
>,30259313,Ctrough,The optimal cut-off value to predict toxicity was Ctrough > 19.2 μg/L.,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],19.2,242950,DB00990,Exemestane
,30259313,Ctrough,GM Ctrough of patients with and without progressive disease (PD) within 3 months was not significantly different (12.0 versus 15.2 μg/L (p = 0.118)).,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],12.0,242951,DB00990,Exemestane
,30259313,Ctrough,GM Ctrough of patients with and without progressive disease (PD) within 3 months was not significantly different (12.0 versus 15.2 μg/L (p = 0.118)).,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],15.2,242952,DB00990,Exemestane
,30259313,PFS,"Patients with <11% versus >11% decrease in SULpeak high at day 14 had a median PFS of 90 days versus 411 days, respectively (p = 0.0013) and more frequently had PD within 3 months: 70 vs 11%, respectively.",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),d,90,242953,DB00990,Exemestane
,30259313,PFS,"Patients with <11% versus >11% decrease in SULpeak high at day 14 had a median PFS of 90 days versus 411 days, respectively (p = 0.0013) and more frequently had PD within 3 months: 70 vs 11%, respectively.",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),d,411,242954,DB00990,Exemestane
,16361559,area under the plasma concentration versus time curve (AUC),"There was no significant effect of exemestane on the area under the plasma concentration versus time curve (AUC) of tamoxifen at steady state before [3.04 mg h/L; 90% confidence interval (90% CI), 2.71-3.44] and during exemestane treatment (3.05 mg h/L; 90% CI, 2.72-3.41).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[h·mg] / [l],3.04,243415,DB00990,Exemestane
,16361559,area under the plasma concentration versus time curve (AUC),"There was no significant effect of exemestane on the area under the plasma concentration versus time curve (AUC) of tamoxifen at steady state before [3.04 mg h/L; 90% confidence interval (90% CI), 2.71-3.44] and during exemestane treatment (3.05 mg h/L; 90% CI, 2.72-3.41).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[h·mg] / [l],3.05,243416,DB00990,Exemestane
,16361559,Oral clearance,"Oral clearance of exemestane averaged 602 L/h based on an average plasma exemestane AUC of 41.5 microg h/L (90% CI, 36.7-62.6).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[l] / [h],602,243417,DB00990,Exemestane
,16361559,AUC,"Oral clearance of exemestane averaged 602 L/h based on an average plasma exemestane AUC of 41.5 microg h/L (90% CI, 36.7-62.6).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[h·μg] / [l],41.5,243418,DB00990,Exemestane
,30700929,number of treatments cycle,"The median number of treatments cycle was 5.2 (20.8 weeks) with 2 patients still on treatment at the data cut-off date of October, 2017.","Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30700929/),,5.2,247303,DB00990,Exemestane
,30700929,progression-free survival (PFS),The median progression-free survival (PFS) was 7.6 months.,"Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30700929/),month,7.6,247304,DB00990,Exemestane
,34196874,progression-free survival,"The median progression-free survival was 9.41 months for the additional 21 patients, who experienced grade 3/4 AEs of neutropenia (38%), thrombocytopenia (9.5%), anemia (9.5%), and fatigue (9.5%).","Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34196874/),month,9.41,258405,DB00990,Exemestane
,21404279,bioavailability,"Exemestane, a novel steroidal aromatase inactivator used in the treatment of advanced breast cancer has limited bioavailability (42%) due to poor solubility, extensive first-pass metabolism, and also the absorption is dependent on formulation type and food.",Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404279/),%,42,260071,DB00990,Exemestane
